This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.
GSK (GSK) Stock Moves -1.04%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, GSK (GSK) stood at $36.29, denoting a -1.04% change from the preceding trading day.
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Zacks Equity Research
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
GSK (GSK) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $36.67, marking a +0.25% move from the previous day.
Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why
by Zacks Equity Research
Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.
Why GSK (GSK) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, GSK (GSK) closed at $37.56, indicating a +0.59% shift from the previous trading day.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
GSK (GSK) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
GSK (GSK) closed at $37.10 in the latest trading session, marking a +1.23% move from the prior day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study
by Zacks Equity Research
Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
by Zacks Equity Research
AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.
GSK (GSK) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.89 in the latest trading session, marking a -0.55% move from the prior day.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $36.09 in the latest trading session, marking a -0.44% move from the prior day.
GSK (GSK) Stock Moves -1.14%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $37.28, moving -1.14% from the previous trading session.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $37.71, marking a +0.75% move from the previous day.
CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns
by Zacks Equity Research
Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
by Zacks Equity Research
Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $37.48, moving +0.35% from the previous trading session.
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
by Zacks Equity Research
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia
by Zacks Equity Research
GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.
Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data
by Zacks Equity Research
Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $36.76, marking a -0.27% move from the previous day.
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
by Zacks Equity Research
Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.
GSK (GSK) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
GSK (GSK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.